Designed to mirror ATMA’s Health Canada approved N500 Phase II Psilocybin Clinical Trial for frontline healthcare professionals CALGARY, AB, April 13, 2023 /PRNewswire/ – ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.